
UnitedHealth (UNH) Is About to Report Q2 Earnings on July 29. Here Is What to Expect
Elevate Your Investing Strategy:
Take advantage of TipRanks Premium at 50% off! Unlock powerful investing tools, advanced data, and expert analyst insights to help you invest with confidence.
Meanwhile, revenues are expected to increase by 13% from the year-ago quarter to $111.5 billion, according to data from the TipRanks Forecast page. It's important to note that UNH has an impressive track record with earnings, having exceeded EPS estimates in eight out of the past nine consecutive quarters.
On July 24, UnitedHealth Group (UNH) revealed in an SEC filing that it is under formal investigation by the Department of Justice (DOJ) over its Medicare billing practices. The company said it is cooperating with both civil and criminal probes into whether it improperly raised patient diagnoses to secure higher payments from the government.
J.P. Morgan analyst Lisa Gill remains optimistic ahead of UnitedHealth's earnings, viewing the DOJ probe as part of a broader industry trend. She maintained an Overweight rating on the stock, expecting a potential rebound despite near-term uncertainty.
Analyst's Views Ahead of UNH's Q2 Earnings
Heading into the Q2 print, Deutsche Bank analyst George Hill lowered his price target to $328 from $362 but reiterated a Buy rating. The analyst noted that investor sentiment 'has deteriorated significantly' due to a series of unfavorable news. The top-rated analyst lowered his estimates, citing ongoing concerns around Optum Health, the company's healthcare services unit.
Also, Leerink Partners analyst Whit Mayo lowered the price target for UNH stock to $340 from $355 and reiterated a Buy rating. He remains 'cautiously optimistic' about the stock heading into Q2 earnings, given the challenging backdrop.
Options Traders Anticipate a Large Move
Using TipRanks' Options tool, we can see what options traders are expecting from the stock immediately after its earnings report. The expected earnings move is determined by calculating the at-the-money straddle of the options closest to expiration after the earnings announcement. If this sounds complicated, don't worry; the Options tool does this for you.
Indeed, it currently says that move in either direction.
Is UNH a Good Buy Now?
Turning to Wall Street, UNH stock has a Moderate Buy consensus rating based on 18 Buys, five Holds, and one Sell assigned in the last three months. At $348.12, the average UnitedHealth stock price target implies a 23.86% upside potential.

Try Our AI Features
Explore what Daily8 AI can do for you:
Comments
No comments yet...
Related Articles


Business Insider
an hour ago
- Business Insider
'$35 Trillion in Home Equity': Home Depot Stock (NYSE:HD) Gains as new Opportunity Uncovered
Just last week, we found out that home improvement stock Home Depot (HD) has a major potential win on its hands as its market share represented a major chunk of the home improvement market. But now, a slightly different study emerged that drives the point home even harder. It turns out that Americans are sitting on a whopping $35 trillion in home equity, and that could make for a major win for Home Depot. That was enough for investors, who sent Home Depot shares up nearly 1.5% in Monday afternoon's trading. Elevate Your Investing Strategy: Take advantage of TipRanks Premium at 50% off! Unlock powerful investing tools, advanced data, and expert analyst insights to help you invest with confidence. The report spelled it out: Americans currently are sitting on the highest level of home equity ever seen. While banks and mortgage originators were in line for big wins here, especially if interest rates start to drop again, there was also a titanic opportunity afoot for home improvement retailers. And since Home Depot controls a hefty portion of that market, that puts it right in line for a strong win. A win it will have to share with its competitors, certainly, but a win nonetheless. A New Distribution Center Emerges Meanwhile, remember when Home Depot announced plans to close a distribution center in Missouri? It turns out that it may have closed a door, but opened a window at the same time. Home Depot recently opened a new Stocking Distribution Center in Joliet, Illinois. The new center will mean 200 new jobs for the region, and came with plenty of support from '…the state and the local community,' noted Mark Holifield, Home Depot's Supply Chain senior vice president. The combination of the distribution center and the Rapid Deployment Center Home Depot reportedly has next door to it will offer Home Depot much more rapid restock and should also improve customer service. Is Home Depot a Good Long-Term Buy? Turning to Wall Street, analysts have a Moderate Buy consensus rating on HD stock based on 18 Buys and six Holds assigned in the past three months, as indicated by the graphic below. After a 3.78% rally in its share price over the past year, the average HD price target of $428.12 per share implies 12.77% upside potential.


Business Insider
an hour ago
- Business Insider
Why Is Celcuity Stock (CELC) Up 210% Today?
Celcuity (CELC) stock rocketed higher on Monday after the clinical-stage biotechnology company announced positive topline results from the PIK3CA wild-type cohort of the Phase 3 VIKTORIA-1 clinical trial. This trial is focused on the study of gedatolisib plus fulvestrant with and without palbociclib versus fulvestrant as a treatment for adults with hormone receptor (HR)-positive, human epidermal growth factor receptor 2 (HER2)-negative, PIK3CA wild-type, locally advanced or metastatic breast cancer. Elevate Your Investing Strategy: Take advantage of TipRanks Premium at 50% off! Unlock powerful investing tools, advanced data, and expert analyst insights to help you invest with confidence. The big news here is that the gedatolisib triplet showed statistically significant and clinically meaningful improvement in progression-free survival (PFS), reducing the risk of progression or death by 76% when compared to fulvestrant. The gedatolisib doublet also showed statistically significant and clinically meaningful improvement in PFS, reducing the risk of progression or death by 67% compared to fulvestrant. Sara Hurvitz, co-investigator of the Celcuity clinical trial, said the results were 'potentially practice-changing.' She noted that 'we have not seen Phase 3 results in patients with HR-positive, HER2-negative advanced breast cancer before where there was a quadrupling of the likelihood of survival without disease progression relative to the study control.' Celcuity Stock Movement Today Celcuity stock was up 212.35% during pre-market trading on Monday, following a 1.99% dip on Friday. The company's shares were also up 5.19% year-to-date but down 23.29% over the past 12 months. Today's rally came with heavy trading, as some 5 million shares changed hands, compared to a three-month daily average of about 250,000 units. Is Celcuity Stock a Buy, Sell, or Hold? Turning to Wall Street, the analysts' consensus rating for Celcuity is Strong Buy, based on seven Buy ratings over the past three months. With that comes an average CELC stock price target of $28.25, representing a potential 105.16% upside for the shares.


Business Insider
an hour ago
- Business Insider
Morgans Keeps Their Buy Rating on Northern Star Resources Ltd (NESRF)
Morgans analyst Ross Bennett maintained a Buy rating on Northern Star Resources Ltd today and set a price target of A$21.00. The company's shares closed yesterday at $10.31. Elevate Your Investing Strategy: Take advantage of TipRanks Premium at 50% off! Unlock powerful investing tools, advanced data, and expert analyst insights to help you invest with confidence. Bennett covers the Basic Materials sector, focusing on stocks such as Regis Resources Limited, Northern Star Resources Ltd, and Catalyst Metals Limited. According to TipRanks, Bennett has an average return of 17.5% and a 65.52% success rate on recommended stocks. In addition to Morgans, Northern Star Resources Ltd also received a Buy from Canaccord Genuity's Tim McCormack in a report issued on July 25. However, on the same day, UBS maintained a Hold rating on Northern Star Resources Ltd (Other OTC: NESRF). Based on Northern Star Resources Ltd's latest earnings release for the quarter ending December 31, the company reported a quarterly revenue of $2.87 billion and a net profit of $506.4 million. In comparison, last year the company earned a revenue of $2.25 billion and had a net profit of $198.5 million